Can a single infusion tame tough lupus?

NCT ID NCT07748156

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called SNC116 in people with refractory systemic lupus erythematosus (SLE), a form of lupus that hasn't improved with standard treatments. The study aims to see if a single intravenous infusion of SNC116 is safe and tolerable, and to get a preliminary look at whether it might reduce disease activity. About 28 adults aged 18 to 65 with active lupus will participate, with researchers monitoring for side effects and any signs of improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SNC116, an experimental drug given as a single intravenous infusion
What this could lead to
If SNC116 proves safe and shows promise, it could offer a new treatment option for people with lupus that hasn't responded to standard therapies.
What could go wrong
This is a very early, small study focused mainly on safety. The drug may not effectively control lupus, and there are risks of side effects or serious adverse events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.